# Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

> **NCT01425749** · EARLY_PHASE1 · COMPLETED · sponsor: **Craig L Slingluff, Jr** · enrollment: 25 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** recMAGE-A3 + AS15 ASCI

## Key facts

- **NCT ID:** NCT01425749
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-07
- **Final completion:** 2015-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425749, "Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT01425749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*